Finance

Beta
Lists
TRDA:NASDAQ
Entrada Therapeutics Inc
$7.07
-0.28%
(-0.020) 1D
$7.07
0.00% (0.00)
After hours
Closed: Jun 22, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRDA...
Open
$7.17
High
$7.37
Low
$6.91
Mkt. cap
274.46M
Avg. vol.
538.41K
Volume
4.00
52-wk high
$16.45
52-wk low
$4.93
EPS
-$4.00
Beta
-0.26
Shares outstanding
38.82M
No. of employees
152
Open
$7.17
High
$7.37
Low
$6.91
Mkt. cap
274.46M
Avg. vol.
538.41K
Volume
4.00
52-wk high
$16.45
52-wk low
$4.93
EPS
-$4.00
Beta
-0.26
Shares outstanding
38.82M
No. of employees
152
News stories
From sources across the web
About Entrada Therapeutics Inc
CEO-
Employees152
Founded2016
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiteentradatx.com
Analyst Ratings
Based on 8 analysts giving stock ratings to TRDA in the past 3 months
Strong Buy
Buy
7
Hold
1
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for TRDA in the last 3 months.
Highest
Current $7.07
$25.00 (+253.61%)
Average
$18.75 (+165.21%)
Lowest
$10.00 (+41.44%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$17.00
+140.5%
06/05/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$23.00
+225.3%
06/03/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
$10.00
+41.4%
06/03/2026
Ram Selvaraju
H.C. Wainwright
Hold
Downgraded
-
-
05/08/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/07/2026
Myles Minter
William Blair
Buy
Maintained
-
-
05/07/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$25.00
+253.6%
05/05/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
-
-
04/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.95M
1.61M
1.30M
875.00K
Cost of goods sold
37.88M
38.36M
32.26M
33.05M
Cost of revenue
37.88M
38.36M
32.26M
33.05M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.92M
10.30M
9.35M
10.12M
Operating expense
10.92M
10.30M
9.35M
10.12M
Total operating expenses
48.80M
48.66M
41.61M
43.18M
Operating income
-46.85M
-47.05M
-40.31M
-42.30M
Other non operating income
-
-
-
-
EBT including unusual items
-42.92M
-43.48M
-39.07M
-39.68M
EBT excluding unusual items
-42.92M
-43.48M
-37.17M
-39.68M
Income tax expense
178.00K
654.00K
92.00K
38.00K
Effective tax rate
-0.41%
-1.50%
-0.24%
-0.10%
Other operating expenses
-
-
-
-
Net income
-43.10M
-44.13M
-39.16M
-39.72M
Net profit margin
-2,210.41%
-2,734.45%
-3,014.93%
-4,539.09%
Earnings per share
-1.04
-1.06
-0.94
-0.95
Interest and investment income
3.92M
3.57M
3.14M
2.62M
Interest expense
-
-
-
-
Net interest expenses
3.92M
3.57M
3.14M
2.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
-45.82M
-45.82M
-39.42M
-41.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer